JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB228411

Anti-LAG-3 antibody [EPR20294-96]

Be the first to review this product! Submit a review

|

(2 Publications)

Rabbit Recombinant Monoclonal LAG-3 antibody. Suitable for Flow Cyt and reacts with Mouse samples. Cited in 2 publications.

View Alternative Names

CD223, Lymphocyte activation gene 3 protein, LAG-3, Activation-induced cytidine deaminase-linked autoimmunity protein, Aida, Lag3

1 Images
Flow Cytometry - Anti-LAG-3 antibody [EPR20294-96] (AB228411)
  • Flow Cyt

Supplier Data

Flow Cytometry - Anti-LAG-3 antibody [EPR20294-96] (AB228411)

Flow cytometric analysis of mouse primary splenocytes treated with 2.5μg/ml concanavalin A for 72h labeling LAG-3 with ab228411 at 1/600 dilution (right) compared with a Rabbit IgG monoclonal [EPR25A] - Isotype Control (ab172730)(left). Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) at 1/2000 dilution was used as the secondary antibody.

Mouse primary splenocytes treated with 2.5μg/ml concanavalin A for 72h then surface stained with anti-mouse CD3 (Y axis) and ab228411. Only CD3+ population gives a positive signal for Lymphocyte Activation Gene 3. Gated on total viable cells.

  • Carrier free

    Anti-LAG-3 antibody [EPR20294-96] - BSA and Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR20294-96

Isotype

IgG

Carrier free

No

Reacts with

Mouse

Applications

Flow Cyt

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Mouse": { "FlowCyt-species-checked": "testedAndGuaranteed", "FlowCyt-species-dilution-info": "1/600", "FlowCyt-species-notes": "<p></p>" } } }

Product details

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

LAG-3 also known as CD223 is a transmembrane protein with a mass of approximately 70 kDa. It acts as a checkpoint molecule similar to CTLA-4 and PD-1 in the immune system. LAG-3 is expressed on activated T cells natural killer cells and some dendritic cells. It interacts with its ligand MHC class II leading to inhibition of cellular proliferation and cytokine secretion an important part of immune response regulation.
Biological function summary

LAG-3 is involved in maintaining immune homeostasis and preventing autoimmunity. It is not part of a complex but works in synergy with other immune checkpoint molecules. When interacting with MHC class II LAG-3 transmits inhibitory signals that attenuate immune cell responses. Its role in immune regulation helps to balance immune activation and tolerance which is essential for preventing tissue damage while protecting against pathogens.

Pathways

The inhibitory role of LAG-3 integrates into the T cell receptor (TCR) signaling pathway and is also linked to the PD-1 signaling pathway. In TCR signaling LAG-3 negatively regulates T cell activation. LAG-3 is functionally related to proteins like PD-1 and CTLA-4 sharing similar roles in immune checkpoint pathways that are critical for maintaining immune balance.

LAG-3 has links to cancer and autoimmune diseases. In cancer LAG-3 expression on tumor-infiltrating lymphocytes correlates with immune evasion by tumors. This relationship appears in various cancers including melanoma and renal cell carcinoma. In autoimmune diseases LAG-3's expression on regulatory T cells helps control conditions such as multiple sclerosis. It collaborates with CTLA-4 in modulating immune responses that prevent excessive immune activation and tissue damage associated with autoimmunity.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Lymphocyte activation gene 3 protein. Inhibitory receptor on antigen activated T-cells (PubMed : 12209638, PubMed : 12421911, PubMed : 12672063, PubMed : 15100286, PubMed : 15634887, PubMed : 30580966, PubMed : 35413245, PubMed : 35761082, PubMed : 38483996, PubMed : 39209860). Delivers inhibitory signals upon binding to ligands, such as MHC class II, its main ligand present at the surface of antigen-presenting cells (APCs), and FGL1, which is secreted by hepatocytes and certain types of tumor cells (PubMed : 12209638, PubMed : 12421911, PubMed : 30349037, PubMed : 30580966, PubMed : 35413245, PubMed : 35761082, PubMed : 39209860). Ligand-binding initiates a signaling that inhibits the T-cell receptor (TCR) in the immunological synapse, preventing T-cell activation (PubMed : 12209638, PubMed : 12421911, PubMed : 12672063, PubMed : 15100286, PubMed : 15634887). Mechanistically, ligand-binding promotes (1) ubiquitination of the KIEELE motif, unleashing the RRFSALE motif from the membrane and (2) leading to the formation of condensates with the TCR component CD3E, thereby disrupting the association between CD3E and LCK and preventing TCR activation (PubMed : 40101708, PubMed : 40592325). May inhibit antigen-specific T-cell activation in synergy with PDCD1/PD-1 (PubMed : 21300912). Negatively regulates the proliferation, activation, effector function and homeostasis of both CD8(+) and CD4(+) T-cells (PubMed : 12209638, PubMed : 12421911, PubMed : 12672063, PubMed : 15100286, PubMed : 15634887). Also mediates immune tolerance : constitutively expressed on a subset of regulatory T-cells (Tregs) and contributes to their suppressive function (PubMed : 15485628). Also acts as a negative regulator of plasmacytoid dendritic cell (pDCs) activation (PubMed : 19201841).. The LAG3-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival.. Secreted lymphocyte activation gene 3 protein. May function as a ligand for MHC class II (MHC-II) on antigen-presenting cells (APC), promoting APC activation/maturation and driving Th1 immune response.
See full target information Lag3

Publications (2)

Recent publications for all applications. Explore the full list and refine your search

International journal of medical sciences 22:3556-3564 PubMed40959576

2025

Vascular Endothelial Protection Effects of Root Aqueous Extracts on LPS-induced Rat Vascular Damage.

Applications

Unspecified application

Species

Unspecified reactive species

Li-Hsien Chen,Sheau-Chung Tang,Shu-Er Yang,Erl-Shyh Kao

Anti-cancer drugs 36:447-458 PubMed39960386

2025

The tetravalent, bispecific properties of FS118, an anti-LAG-3/PD-L1 antibody, mediate LAG-3 shedding from CD4 + and CD8 + tumor-infiltrating lymphocytes.

Applications

Unspecified application

Species

Unspecified reactive species

Claire S Reader,Wenjia Liao,Beatrice J Potter-Landua,Christel Séguy Veyssier,Claire J Seal,Neil Brewis,Michelle Morrow
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com